Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.

Daniel Tobias Michaeli Julia Caroline Michaeli Tobias Boch Thomas Michaeli

Published in: Cardiovascular drugs and therapy (2022)

For primary cardiovascular prevention, a combination therapy of icosapent ethyl plus statin is a cost-effective use of resources compared to statin monotherapy. For secondary prevention, icosapent ethyl, ezetimibe, evolocumab, and alirocumab increase patient benefit at different economic costs.

Keyphrases

combination therapy
low density lipoprotein
cardiovascular disease
coronary artery disease
ionic liquid
randomized controlled trial
open label